A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Deucrictibant (Primary)
- Indications Hereditary angioedema
- Focus Proof of concept; Therapeutic Use
- Acronyms CHAPTER-1; HAE CHAPTER-1
- Sponsors Pharvaris
- 05 Sep 2024 According to a Pharvaris media release, data from this study will be presented at the Bradykinin Symposium in Dallas, TX from September 13-14, 2024
- 28 Aug 2024 According to a Pharvaris media release, data from this study will be presented at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany.
- 04 Jun 2024 According to a Pharvaris media release, data from this study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.